B. Metch

发表

Recruitment of Caribbean female commercial sex workers at high risk of HIV infection.

J. Pape, Karine Sévère, M. Deschamps, 2013, Revista panamericana de salud publica = Pan American journal of public health.

The Carotene and Retinol Efficacy Trial (CARET) to prevent lung cancer in high-risk populations: pilot study with cigarette smokers.

G. Omenn, M. Thornquist, G. Goodman, 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Determinants of Enrollment in a Preventive HIV Vaccine Trial: Hypothetical Versus Actual Willingness and Barriers to Participation

E. Vittinghoff, S. Buchbinder, S. Scheer, 2004, Journal of acquired immune deficiency syndromes.

A Demographic Analysis of Racial/Ethnic Minority Enrollment Into HVTN Preventive Early Phase HIV Vaccine Clinical Trials Conducted in the United States, 2002-2016

M. Andrasik, B. Metch, Katherine Foy Huamani, 2018, Public health reports.

Title Strategies for recruitment to a population-based lung cancer prevention trial : The CARET experience with heavy smokers Permalink

G. Goodman, B. Metch, 2008 .

Strategies for Recruitment to a Population-based Lung Cancer Prevention Trial: The CARET Experience with Heavy Smokers I

G. Omenn, M. Thornquist, G. Goodman, 2008 .

Strategies for recruitment to a population-based lung cancer prevention trial: the CARET experience with heavy smokers. Beta-Carotene and Retinol Efficacy Trial.

G. Omenn, M. Thornquist, G. Goodman, 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults

W. Blattner, D. Weiner, S. Kalams, 2012, PloS one.

The Carotene and Retinol Efficacy Trial (CARET) to prevent lung cancer in high-risk populations: pilot study with asbestos-exposed workers.

G. Omenn, S. Barnhart, M. Thornquist, 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa?

J. Kublin, L. Bekker, G. Churchyard, 2013, Vaccine.

A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.

D. Montefiori, M. McElrath, P. Goepfert, 2011, Vaccine.

Chemoprophylaxis vaccination: Phase 1 study to explore stage-specific immunity to Plasmodium falciparum in U.S. adults.

J. Kublin, K. Stuart, S. Kappe, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.

B. Haynes, J. Fuchs, S. Kalams, 2009, Vaccine.

Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients.

R. Coombs, L. Baden, J. Dragavon, 2010, JAMA.

Primary tubal infertility in relation to the use of an intrauterine device.

W. Chow, N. Weiss, D. Moore, 1985, The New England journal of medicine.

Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.

Donald K Carter, Ian Frank, Beryl Koblin, 2013, The Journal of infectious diseases.

Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.

J. Kublin, L. Corey, L. Bekker, 2011, The Lancet. Infectious diseases.

Feasibility of Identifying a Female Sex Worker Cohort at High Risk of HIV Infection in the Caribbean for HIV Vaccine Efficacy Trials: Longitudinal Results of HVTN 907

M. Deschamps, Y. Donastorg, C. Morgan, 2016, Journal of acquired immune deficiency syndromes.

Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines.

S. Self, D. Montefiori, M. McElrath, 2004, The Journal of infectious diseases.

Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responses.

M. Seaman, R. Dolin, L. Baden, 2012, Vaccine.

Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men

J. Kublin, P. Gilbert, L. Corey, 2015, PloS one.

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials

S. Hammer, J. Kublin, J. Mascola, 2015, PloS one.

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.

J. Kublin, P. Gilbert, L. Corey, 2014, The Lancet. Infectious diseases.

The association between participant characteristics and serum concentrations of beta-carotene, retinol, retinyl palmitate, and alpha-tocopherol among participants in the Carotene and Retinol Efficacy Trial (CARET) for prevention of lung cancer.

G. Omenn, M. Thornquist, G. Goodman, 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

The effect of long-term beta-carotene and vitamin A administration on serum concentrations of alpha-tocopherol.

G. Omenn, G. Goodman, B. Metch, 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

The HVTN Protocol 903 Vaccine Preparedness Study: Lessons Learned in Preparation for HIV Vaccine Efficacy Trials

S. Buchbinder, C. Beyrer, J. Pape, 2008, Journal of acquired immune deficiency syndromes.

Risk behavior among women enrolled in a randomized controlled efficacy trial of an adenoviral vector vaccine to prevent HIV acquisition

S. Buchbinder, D. Metzger, M. Tyndall, 2013, AIDS.

Feasibility of Identifying a Cohort of US Women at High Risk for HIV Infection for HIV Vaccine Efficacy Trials: Longitudinal Results of HVTN 906

D. Dunbar, I. Frank, B. Koblin, 2013, Journal of acquired immune deficiency syndromes.

Recruitment of Urban US Women at Risk for HIV Infection and Willingness to Participate in Future HIV Vaccine Trials

D. Dunbar, D. Metzger, I. Frank, 2013, AIDS and Behavior.

Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention.

M. Andrasik, C. Sharpe, B. Metch, 2018, Vaccine.

Erratum: Risk behavior among women enrolled in a randomized controlled efficacy trial of an adenoviral vector vaccine to prevent HIV acquisition (AIDS (2013) 27 (1763-1770))

S. Buchbinder, Y. Donastorg, R. Novak, 2013 .

Safety and efficacy assessment of the HVTN 503/Phambili Study: A double-blind randomized placebo-controlled test-of-concept study of a Clade B-based HIV-1 vaccine in South Africa

J. Kublin, L. Corey, G. Gray, 2011 .

Primary Tubal Infertility in Relation to the use of an Intrauterine Device

W. Chow, N. Weiss, D. Moore, 1985 .

IUD use and subsequent tubal ectopic pregnancy.

W. Chow, N. Weiss, D. Moore, 1986, American journal of public health.

Ectopic pregnancy in relation to previous induced abortion.

W. Chow, N. Weiss, J. Daling, 1985, JAMA.

Testing the Decline-of-Community Thesis: Neighborhood Organizations in Seattle, 1929 and 1979

Barrett A. Lee, A. Guest, Avery M. Guest, 1984, American Journal of Sociology.

Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein

Allan C. deCamp, J. Kublin, S. Omarjee, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

P15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study?

G. Churchyard, Z. Moodie, K. Mlisana, 2009, Retrovirology.

Lessons From a Multisite International Trial in the Caribbean and South America of an HIV-1 Canarypox Vaccine (ALVAC-HIV vCP1452) With or Without Boosting With MN rgp120

D. Montefiori, S. Gurunathan, D. Lawrence, 2007, Journal of acquired immune deficiency syndromes.

Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.

Allan C. deCamp, J. Kublin, S. Buchbinder, 2016, Current opinion in virology.

Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.

J. Kublin, J. Fuchs, N. Sardesai, 2013, The Journal of infectious diseases.

Importance of human papillomavirus endemicity in the incidence of cervical cancer: an extension of the hypothesis on sexual behavior.

G. Omenn, S. Franceschi, J. Kaldor, 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.

J. Kublin, P. Gilbert, L. Corey, 2014, The Lancet. Infectious diseases.